Brief: Natco Pharma Says API Unit In Chennai Receives Establishment Inspection Report From U.S. FDA
13/02/2026 03:48
Feb 13 (Reuters) - Natco Pharma Ltd NATP.NS: NATCO PHARMA - API UNIT IN CHENNAI RECEIVES ESTABLISHMENT INSPECTION REPORT FROM U.S. FDA NATCO PHARMA - API UNIT IN CHENNAI RECEIVES EIR FROM U.S. FDA NATCO PHARMA - COMPANY RECEIVED SEVEN OBSERVATIONS NATCO PHARMA - RECEIVED EIR CLASSIFIED AS VOLUNTARY ACTION INDICATED Source text: ID:nBSEM8T3j Further company coverage: NATP.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Natco Pharma
See all newsBrief: Natco Pharma Launches Carboplatin Injection In Us With Teyro Labs
India's Natco Pharma jumps after launching ovarian cancer drug in US
Brief: Natco Pharma Announces Launch Of Carboplatin Injection In The U.S. Market
Brief: Natco Pharma To Increase Its Investment In Egenesis To $16.70 Million
Brief: Natco Pharma Approves Rights Issue Up To 12.79 Billion Rupees